High Throughput Screening Market Forecasts to 2030 - Global Analysis By Product, Technology, Application, End User and By Geography

According to Stratistics MRC, the Global High Throughput Screening Market is accounted for $25.70 billion in 2023 and is expected to reach $62.75 billion by 2030 growing at a CAGR of 13.6% during the forecast period. A crucial procedure in biotechnology, pharmaceutical, and life sciences research is high-throughput screening, or HTS. In order to determine which chemicals are active or to learn more about how they affect biological systems, a vast number of chemical or biological molecules must be rapidly tested. Furthermore, HTS processes thousands, even millions, of samples in a comparatively short amount of time by utilizing automated and robotic systems. Drug discovery relies heavily on this technology, which aids in the identification of possible drug candidates, the investigation of their interactions with biological targets, and the evaluation of their safety and effectiveness.

According to the data published by the Congressional Budget Office, in 2021, it has been observed that pharmaceutical industries have spent nearly USD 200 billion on research and development in 2020 globally compared to USD 83 million in 2019.

Market Dynamics:

Driver:

Drug development and discovery

Modern drug discovery and development efforts are built on the foundation of HTS. Innovative medications are always being sought after by the pharmaceutical industry to treat a variety of illnesses, from cancer to uncommon genetic conditions. Moreover, thousands of compounds can be quickly screened with HTS to find promising drug candidates, greatly accelerating and cutting costs associated with the drug development process.

Restraint:

Large initial expenses

HTS technologies and systems require large upfront costs. For startups, smaller research organizations, and academic institutions in particular, the cost of advanced assay technologies, robotics, and high-throughput screening equipment can be prohibitive. Additionally, external funding or collaborations are frequently required to cover these upfront costs.

Opportunity:

Integration of AI and machine learning

HTS procedures could undergo a revolution if machine learning and artificial intelligence (AI) are integrated. These technologies can predict the behavior of compounds, analyze large datasets, and enhance screening procedures. Furthermore, the efficiency and financial viability of drug discovery can be greatly increased by using AI-driven algorithms to greatly improve hit identification, lead optimization, and compound prioritization.

Threat:

Lack of economic clarity

The HTS market may be significantly impacted by recessions, downturns in the economy, or shifts in research funding. HTS research and development may slow down as a result of reduced funding from both the pharmaceutical industry and academia, which would limit investment in and innovation from cutting-edge technologies. Moreover, long-term projects can be derailed, and access to necessary resources can be impeded by economic instability.

COVID-19 Impact:

The high-throughput screening (HTS) market was impacted by the COVID-19 pandemic in a number of ways. The need for quick drug discovery and vaccine development greatly accelerated the adoption of HTS technologies to screen and identify possible treatments for the virus, even though supply chain disruptions, laboratory closures, and resource shortages initially slowed down research and development activities. This led to an increase in demand for vaccine development, biological research on the virus, and screening of antiviral compounds in the HTS market. Furthermore, the pandemic highlighted the significance of automated and remote-capable HTS systems, enabling researchers to carry out their work while abiding by safety precautions and social distancing.

The Cell-based Assays segment is expected to be the largest during the forecast period

In the high-throughput screening (HTS) market, cell-based assays hold the largest market share. A vital part of drug discovery and research, cell-based assays use living cells to examine their reactions to different substances. In addition to facilitating the screening of compounds in more biologically relevant contexts, they offer insightful information about the possible toxicity and efficacy of therapeutic candidates. Moreover, cell-based assays are fundamental to the HTS market, accounting for a sizeable portion of the market share, and have a wide range of applications, such as drug screening, toxicity testing, and target identification. They play a special role in figuring out possible treatment candidates and comprehending the intricate mechanisms underlying diseases.

The Drug Discovery segment is expected to have the highest CAGR during the forecast period

In the high-throughput screening (HTS) market, drug discovery is the segment with the highest CAGR. The rising demand for novel medications and treatments across a range of disease states is a major driver of market growth for HTS. Drug discovery, which includes optimizing lead compounds and identifying possible drug candidates, mainly depends on HTS technologies for quick and effective screening. Additionally, the development of new drugs has accelerated due to the streamlining of drug discovery processes brought about by advances in automation, robotics, and data analysis.

Region with largest share:

The high-throughput screening (HTS) market is anticipated to hold the largest share in the North American region. Significant investments in research and development, a well-established pharmaceutical and biotechnology industry, and a strong need for cutting-edge drug discovery and development technologies are all considered contributing factors to this dominance. Further bolstering North America's standing as a major player in the HTS market is the existence of top HTS equipment manufacturers and research facilities, as well as supportive government initiatives and funding. Furthermore, North America leads the world in the use of HTS technologies due to the region's strong healthcare system and emphasis on precision medicine.

Region with highest CAGR:

In the high-throughput screening (HTS) market, the Asia-Pacific region is growing at the highest CAGR. The growing emphasis on precision medicine in nations like China and India, as well as increased investments in biotechnology and pharmaceutical research, are driving this rapid growth. Clinical trials and drug discovery initiatives find the region appealing due to its large and diverse patient population and cost-effective research and development capabilities. Moreover, a rise in life sciences research endeavors and government backing also play a significant role in the impressive expansion of the Asia-Pacific HTS market, securing the region's standing as a major engine of global HTS market growth.

Key players in the market

Some of the key players in High Throughput Screening market include: GE Healthcare, Danaher Corporation, Agilent Technologies Inc, Tecan Group Ltd., Corning Incorporated, Sigma-Aldrich Corporation, Charles River Laboratories International, Inc, Axxam SpA, Thermo Fisher Scientific, Inc., Hamilton Company, Bio-Rad Laboratories, Inc, Merck KGaA, Promega Corporation, BioTek Instruments, Inc., PerkinElmer Inc., Luminex Corporation , Aurora Biomed Inc, NanoTemper Technologies GmbH, Beckman Coulter Inc. and DIANA Biotechnologies, s.r.o.

Key Developments:

In October 2023, GE HealthCare announced an exclusive global licensing agreement with SOFIE Biosciences (SOFIE), a Virginia, U.S.-based Company, to develop, manufacture and commercialize SOFIE's Gallium-68 and Fluorine-18 labelled diagnostics targeting fibroblast activation protein (FAP). Financial terms were not disclosed.

In August 2023, Danaher will acquire all outstanding Abcam shares for $24 per share in cash, with a total enterprise value of approximately $5.7 billion, including Abcam's assumed debts and net of acquired cash. Danaher plans to fund the acquisition using cash on hand and proceeds from the issuance of commercial paper.

In March 2023, Agilent Technologies Inc announced a multi-year distribution agreement with Proscia® - a leader in digital pathology - to offer a comprehensive digital diagnostic pathology system. Combining Agilent's trusted pathology staining solutions with Proscia's Concentriq® Dx enterprise pathology platform will empower pathology labs to transform diagnostic efficiency and quality to improve patient health outcomes.

Products Covered:

• Consumables
• Instruments
• Services
• Software
• Other Products

Technologies Covered:

• Cell-based Assays
• Lab-on-a-Chip Technology (LOC)
• Label-free Technology
• Ultra High Throughput Screening
• Other Technologies

Applications Covered:

• Drug Discovery
• Biochemical Screening
• Life Sciences Research
• Other Applications

End Users Covered:

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations (CROs)
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances